Pathophysiology and management of acute liver failure

Annals of Gastroenterology

Volumn 23, Issue 4, 2010, Pages 257-265

  Pyleris, E ^a   Giannikopoulos, G ^a   Dabos, K ^a  

^a Gastro intestinal unit   (Greece)

Author keywords

ALF during pregnancy; Fulminant hepatic failure; Paracetamol overdose; Transplantation

Indexed keywords

ACETYLCYSTEINE; ACICLOVIR; ANTIFUNGAL AGENT; CARBAMAZEPINE; CORTICOSTEROID; HALOTHANE; LAMIVUDINE; MANNITOL; NONSTEROID ANTIINFLAMMATORY AGENT; ORNITHINE ASPARTATE; PARACETAMOL; PENICILLIN G; SILIBININ; TUBERCULOSTATIC AGENT; VALPROIC ACID;

ALBUMIN DIALYSIS; BACTERIAL INFECTION; BIOARTIFICIAL LIVER; BLOOD CLOTTING DISORDER; BRAIN DISEASE; BRAIN EDEMA; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE CLASSIFICATION; DRUG OVERDOSE; GRAFT SURVIVAL; HELLP SYNDROME; HEMATOLOGIC DISEASE; HEPATITIS B; HERPES SIMPLEX; HUMAN; INFECTION SENSITIVITY; KIDNEY DISEASE; LIVER FAILURE; LIVER TRANSPLANTATION; LIVING DONOR; LUNG COMPLICATION; METABOLIC DISORDER; MUSHROOM POISONING; MYCOSIS; PATHOPHYSIOLOGY; REVIEW; REYE SYNDROME; SURVIVAL RATE; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; TREATMENT RESPONSE; WILSON DISEASE;

EID: 78449268204     PISSN: 11087471     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (91)

1. Trey C, davidson LS. The management of fulminant hepatic failure, In Popper H, Schaffner F, eds. Progress in liver disease. new York: Grune & Stratton, 1970: 282-298.
2. Bernuau J, ruef B, Benhamou J. Fulminant and subfulminant liver failure: definitions and causes. Semin liver dis 1986; 6:288-294
3. Ogrady JC, Schalm SW, Williams R. Acute liver failure: redefining the syndromes. lancet 1993; 342:273-275
4. OGrady J, Alexander GJM, Hayllar KM, Williams R. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology 1989; 97:439-445
5. lee, W.Acute liver failure. new Engl J Med 1993; 329:1862-1872
6. Trey C. The fulminant hepatic failure surveillance study: brief review of the effects of presumed aetiology and age on survival. CMAJ 1972; 106:525-526
7. Williams R.new directions in acute liver failure. J r Coll Physicians lond 1994; 26:552-559
8. Ellis A, Wendon J. Circulatory, respiratory, cerebral, and renal derangements in acute liver failure: Pathophysiology and management. Semin liver dis 1996; 16: 379-388
9. Prescott LF, Illingworth RN, Critchley JAJH, Stewart MJ, Adam RD, Proudfoot AT. Intravenous n-acetylcysteine: the treatment of choice for paracetamol poisoning. Br Med J 1979; 2: 1097-1100
10. Harrison PM, Keays R, Bray GP, Alexander GJM, Williams R. Improved outcome of paracetamol-induced fulminant hepatic failure by late administration of acetylcysteine. lancrt 1990; 335:1572-1573
11. Keays R, Harrison PM, Wendon J, et al. Intravenous acetylcysteine in paracetamol induced fulminant hepatic failure: a prospective controlled trial. Br Med J 1991; 303: 1026-1029
12. Harrison PM, Wendon J, Gimson AE, et al. Improvement by acetylcysteine of haemodynamics and oxygen transport in fulminant hepatic failure. n Engl J Med 1991; 324:1852-1858
13. Acharya SK, dasarathy S, Kumer TL, et al. Fulminant hepatitis in tropical population: clinical course, cause, and early predictors of outcome. Hepatology 1996; 23:1448-1455
14. Tibbs C, Williams R. Viral causes and management of acute liver failure. J Hepatol 1995; 22(Suppl. 1): 68-73
15. Fagan EA, Williams R. Fulminant viral hepatitis. Br Med Bull 1990; 46: 462-80
16. Hoofnagle J, Carithers R, Jr Shapiro C, Asher N. Fulminant hepatic failure; Summary of a Workshop. Hepatology 1995; 21: 240-252
17. Smedile A, Farcy P, Verme G et al. Influence of delta infection on severity of hepatitis B. lancet 1982; 2:945-947
18. Fagan EA. Acute liver failure of unknown pathogenesis: the hidden agenda. Hepatology 1994; 19:1307-1312
19. Takahashi Y, Shimizu M. Aetiology and prognosis of fulminant viral hepatitis in Japan::: a multi center study. J Gastroenterol Hepatol 1991; 6:159-164
20. Tameda Y, Hamada M, Takase K, nakano T, Kosaka Y. Fulminant hepatic failure caused by ecarazine hydrochloride [a hydralazine derivative]. Hepatology 1996; 23: 465-470.
21. Ellis AJ, Wendon JA, Portmann B, Williams R. Acute liver damage and ecstasy ingestion. Gut 1996; 38: 454-458
22. McCullough AJ, Fleming CR, Thistle JL, et al. diagnosis of Wilson's disease presenting as fulminant hepatic failure. Gastroenterology 1983; 84:161-167
23. Schilsky ML, Sheinberg IH, Sternlieb I.liver transplantation for Wilson's disease: indications and outcome. Hepatology 1994; 19:583-587
24. Hurwitz ES, Barrett MJ, Bregman D, et al. Public health service study of reye's syndrome and medications. report of the main study. J. Am Med Assoc 1987; 257: 1905-1911
25. Bernuau J, Samuel D, durand R, et al.Criteria for emergency liver transplantation in patients with acute viral hepatitis and factor V below 50% of normal: a prospective study. Hepatology 1991; 14:49A
26. Ede RJ, Gimson AE, Bihari D, Williams R. Controlled hyperventilation in the prevention of cerebral oedema in fulminant hepatic failure. J Hepatol 1986; 2:43-51
27. Anonymous. The brain in fulminant hepatic failure. lancet 1991; 338:156-157
28. Williams R, Gimson AE. Intensive liver care and management of acute hepatic failure. dig dis Sci 1991; 36:820-826
29. Keays R, Alexander GJM, Williams R. The safety and the value of extradural intracranial pressure monitors in fulminant hepatic failure. J Hepatol 1993; 18:205-209
30. Hanid MA, davies M, Mellon PJ, et al. Clinical monitoring of intracranial pressure in fulminant hepatic failure. Gut 1980; 21:866-869
31. Canalese J, Gimson AE, davis C, Mellon PJ, davis M, Williams R. Controlled trial of dexamethasone and mannitol for cerebral edema of fulminant hepatic failure. Gut 1982; 23:625-629
32. report from the European Association for the Study of the liver {EASl}. randomised trial of steroid therapy in acute liver failure. Gut 1979; 20:620-623
33. Ware A, Jones RE, Shorey JW, Combes B. A controlled trial of steroid therapy in massive hepatic necrosis. Am J Gastroenterol 1974; 62:130-133
34. rakela J. A double blinded randomized trial of hydrocortisone in acute hepatic failure study group. Gastroenterology 1979; 76:1297
35. Salmeron JM, Tito L, rimola A, et al. Selective intestinal dencontamination in patients with acute liver failure. J Hepatol 1992; 14:280-285
36. rolando N, Harvey F, Brahm J. Fungal infection; a common unrecognized complication of acute liver failure. J Hepatol 1991; 12:1-9
37. rolando N, Gimson AE, Wade J, et al. Prospective controlled trial of selective parenteral and enteral antimicrobial regimen in fulminant liver failure. Hepatology 1993; 17:196-201
38. rolando N, Wade J, Stangou A, et al. Prospective study comparing prophylactic parenteral antimicrobials, with or without enteral decontamination, in patients with acute liver failure. liver Transplant Surg 1996; 2:8-13
39. Harrison PM, OGrady J, Keays R, Alexander GJM, Williams R. Serial prothrombin time as a prognostic indicator in paracetamol induced fulminant hepatic failure. Br Med J 1990; 301:964-966
40. Mackie IJ. The biology of haemostasis and thrombosis. In: Weatherall dJ, ledingham JGG, Warrell dA, eds. Oxford university Press, 1996: 3613-3627
41. OGrady J, langley P, Isola LM, et al. Coagulopathy of fulminant liver disease. Semin liver dis 1986; 6:159-163
42. Pereira SP, langley P, Williams R. The management of abnormalities of hemostasis in acute liver failure. Semin liver dis 1996; 16:403-414
43. Mcdougall Br, Williams R.H2 receptor antagonist in the prevention of acute upper gastrointestinal hemorrhage in fulminant hepatic failure: a controlled trial. Gastroenterology 1978; 74:464-465
44. McCarthy DM. Sucralfate. new Engl J Med 1991; 325:1017-1025
45. Gazzard BG, Henderson JM, Williams R. Early changes in coagulation following a paracetamol overdose and a controlled trial of fresh frozen plasma therapy. Gut 1975; 16:617-620
46. Goldfarb G, lebrec D. Percutaneous cannulation of the internal jugular vein in patients with coagulopathies: an experience based on 1.000 attempts. Anesthesiology 1982; 56:321-323
47. Makin A, Williams R. The current management of paracetamol overdose. Br J Clin Pract 1994; 48:144-1448
48. ring-larsen H, Palazzo U.renal failure in fulminant hepatic failure and terminal cirrhosis: a comparison between incidence, types, and prognosis. Gut 1981; 22:585-591
49. Wilkinson SP, Blendis IK, Williams R. Frequency and type of renal and electrolyte disorders in fulminant hepatic failure. Br Med J 1974; I:186-189
50. Moore K, Taylor G, Ward P, Williams R. Aetiology and management of renal failure in acute liver failure. In: Williams r, Hughes rd, ed. Acute liver Failure: Improved understanding and Better Therapy. Welwyn Garden City, uK: Smith Kline Beecham Pharmaceuticals 1991; 47-53.
51. Bihari D, Gimson AE, Waterson M, Williams R. Tissue hypoxia during fulminant hepatic failure. Crit Care Med 1985; 13:1034-1039
52. Wendon J, Harrison PM, Keays R, Gimson AE, Alexander GJM, Williams R. Effects of vassopressor agents and epoprostenol on systemic hemodynamics and oxygen transport in fulminant hepatic failure. Hepatology 1992; 15:1067-1071
53. Pauwels A, Mostafa-Karan N, Florent C, levy VG. Emergency liver transplantation for acute liver failure: evaluation of london and Clichy criteria. J Hepatol 1997; 26: 62-68
54. Van Thiel D. When should a decision to proceed with transplantation actually be made in cases of fulminant or subfulminant hepatic failure: at admission to hospital or when a donor organ is made avaible? J Hepatol 1993; 17:1-2
55. Hockerstedt K, Isionemi H, Ericzon BG, et al. Is a 3-day waiting list appropriate for patients with acute liver failure? Transplant Proc 1994; 26:1786-1787
56. Bounjema K, Cherqui D, Jaeck D, et al. Auxiliary liver transplantation for fulminant and subfulminant hepatic failure. Transplantation 1995; 59:218-223
57. Metselear HJ, Hesselink EJ, de rave S, et al. recovery of failing liver after auxiliary heterotopic transplantation. lancet 1990; 335:1156-1157
58. Harland RC, Bollinger RR. Extracorporeal hepatic perfusion in the treatment of patients with acute hepatic failure. Transplant rev 1994; 8:73
59. Wang X, Andersson R. Hepatocyte transplantation: A potential treatment for acute liver failure. Scand J Gastroenterol 1995; 30:193-200
60. ringe B, lubbe N, Kuse E, et al. Management of emergencies before and after liver transplantation by early total hepatectomy. Transplant Proc 1993; 25:1090
61. ringe B, lubbe N, Kuse E, Frei U, Pichlmayr R. Total hepatectomy and liver transplantation as two-stage procedure. Ann Surg 1993; 218:3-9
62. Ejlersen E, larsen FS, Pott F, et al. Hepatectomy corrects cerebral hyperperfusion in fulminant hepatic failure. Transplant Proc 1994; 26:1794-1795
63. Makowka L, Cramer D, Hoffman A, et al. The use of a pig liver xenograft for temporary support of a patient with fulminant hepatic failure. Transplantation 1995; 59:1654-1659
64. Cramer D, Sher L, Makowka L. liver xenotransplantation: Clinical experience and future considerations. In: cooper dKC, Kemp E, reemtsma K, White dJG, eds. Xenotransplantation: The Transpantation of Organs and Tissues between Species. Berlin: Springer 1991:559.
65. Ogrady J, Gimson AE, OBrein CJ, et al. Controlled trials of charcoal hemoperfusion and prognosis factors in fulminant hepatic failure. Gastroenterology 1988; 94:1185-1192
66. Bihari D, Hughes RD, Gimson AE, OBrein CJ, et al. Effects of serial resin hemoperfusion in fulminant hepatic failure. Int J Artif Organs 1983; 6:299-302
67. Gazzard BG, Weston MJ, Murraylyon IM, et al. Charcoal hemoperfusion in the treatment of fulminant hepatic failure. lancet 1974; I:1301-1307
68. Sorrentino F. Prime ricercheper la realizzatione di un fegato artificial. Chir Patol Sper 1956; 4:1401-1414
69. ronga J, Podesta L, lePage E, et al. A bioartificial liver to treat severe acute liver failure. Ann Surg 1994; 219:538-546
70. dixitt V. development of a bioartificial liver using isolated hepatocytes, Artif Organs 1994; 18:371-384
71. Kalmot A, ronga J, Watanabe F, demetriou A. Artificial liver support systems. Biotechnol Bioeng 1996; 50:382-391.
72. Hughes RD, Williams R. Assessment of bioartificial liver support in acute liver failure. Int J Artif Organs 1996; 19:3-6.
73. Wang X, Andersson R. Hepatocyte transplantation: a potential treatment for acute liver failure. Scand J Gastroenterol 1995; 30:193-200
74. Bilir B, durham JD, Krystal J, et al. Transjugular intra-portal transplantation of cryopreserved human hepatocytes in a patient with acute liver failure. Hepatology 1996; 24
75. th panhelladic congress of hepatology 200
76. Murali Pathikonda, Santiago J. Munoz. Acute liver failure. Annals of hepatology 2010; 9:7-14
77. Gonzalez-Casas R, Garcia-Buey L, Jones E.A, Gispert JP, Moreno-Otero R. Hepatitis-asociated aplastic anaemiaa syndrome associated with abnormal immunological function. Aliment Pharmacol Ther 30:436-443
78. navaneethan U, Al Mohajer M, Shata M. Hepatitis E and Pregnacy-understanding the pathogenesis. liver Int. 2008; 28:1190-1199
79. dourakis S, Tzemanakis E, deutsch M, Kafiri G, Hadziyannis S. Fulminant hepatic failure as a presenting paraneoplastic manifestation of Hodgkin's disease. Eur J Gastroenterol Hepatol 11:1055-1058
80. rajvanshi P, Kowdley K, Hirota W, Meyers J, Keeffe E. Fulminant Hepatic Failure Secondary to neoplastic Infiltration of the liver. J Clin Gastroenterol 2005; 39:339-343
81. litten J, rodriguez M, Maniaci V. Acute lymphoblastic leucemia Presenting in Fulminant Hepatic Failure. Pediatr Blood Cancer 2006;47:842-845
82. Kaira K, Takise A, Watanabe R, Mori M. Fulminant hepatic failure resulting from small-cell lung cancer and dramatic response of chemotherapy. World J Gastroenterol 2006; 12:2466-2468
83. Alexopoulou A, Koskinas J, deutsch M, delladetsima J, Kountouras d, dourakis S. Acute liver failure as the initial manifestation of hepatic infiltration by a solid tumor: report of 5 cases and review of the literature. Tumori 2006; 92:354-357
84. laggner A, Kleinberger G, Haller J, Czembirek H, drumi W, lenz K. Pulmonale Komplikationen bei Coma hepaticum. leber Magen darm 1982; 12:208-212
85. Plauth M, Cabre E, Campillo B, Kondrup J, Marchesini G, Schutz T, Shenkin A, Wendon J. ESPEn Guidelines on Parenteral nutrition: Hepatology. Clinical nutrition 2009; 28:436-444
86. Craig DGN, lee A, Hayes PC, Simpson KJ. review article: The current management of acute liver failure. Aliment Pharmacol Her 31:345-358
87. Kantola T, Koivusalo A-M, Parmanen S, Hockerstedt K, Isoniemi H. Survival predictors in patients treated with a molecular adsorbent recirculating system. World J Gastroenterol 2009; 15:3015-3024.
88. Mitzner S, Stange J, Klammt S, Koball S, Hickstein H, reisinger E. Albumin dialysis MArS: Knowledge from 10 years of clinical investigation. ASAIO Journal 2009
89. Shakir F, Madhoun M, Whorton J, Harty R. Metastatic Prostatic Carcinoma Presenting as Fulminant Hepatic Failure. Southern Medical Journal 2008; 101: 1049-1050
90. novelli G, rossi M, Ferretti G, Pugliese F, ruberto F, lai Q, et al. Predictive Criteria for the Outcome of Patients with Acute liver Failure Treated With the Albumin dialysis Molecular Adsorbent recirculating System. Therapeutic Apheresis and dialysis 2009; 13:404-412
91. Hayes P, Simpson K. Approach to the patient with Fulminant (Acute) liver Failure. Atlas of Gastroenterology/editor Tadataka Yamada 2003; p118-126